Diamedica Therapeutics Inc. · NASDAQ:DMAC
Diamedica Therapeutics — Investor Presentation (June 2024)
32 slides from Diamedica Therapeutics's investor presentation, Jun 26, 2024
Slide 1: Corporate Presentation
Corporate Presentation WwW SZ DiaMedica MIS THERAPEUTICS ‘Transforming Care for Stroke and Preeclampsia
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements 2D. This presentation contains forward-looking statements within the meaning ofthe US. rvte Secures Ligation Reform Act of 1995 and forward-looking information that are based on the beliefs of and reflect 's current hen used in this the words "cot
Slide 3: Our Mission
OUR MISSION Life-transforming Therapy for Patients with Severe Ischemic Diseases 01 Acute Ischemic Stroke (AIS) (Non-eligible for tPA or thrombectomy) No FDA Approved Therapeutics 02 Preectampsia (PE) 3'@ DiaMedica THERAPEUTICS
Slide 4: Lead Program: DM199 - Novel, Late-Stage Biologic Therapy
Lead Program: DM199 - Novel, Late-Stage Biologic Therapy Com pany ) Recombinant KLK1 (rhKLK1) protein with FDA Fast-Track Designation > Overview Acute Ischemic Stroke (AIS) )- >$10 bition US market opportunity Cash: $46 million ) ~80%6 of patients have no treatment options today? {as of March 31, 20
Slide 5: DiaMedica Pipeline
DiaMedica Pipeline conpouno ipication PRECLINICAL —_ PHASE Puase2 PHASE2/ _ UPCOMING MILESTONES Acute scheme Anticipated interim DM199 Stroke ° hE Enrolment Q1:25 (Rinvecatinase atta) | _o Recombinantkixs | preectampsia GD Aatpatea Poot ot Fetal Growth Restriction ‘Concept Data in 1H‘25 Recmtnantsei
Slide 6: DM199: One Target, Dual Impact - BK2 Receptor Activation in Stroke and PE
DM199: One Target, Dual Impact - BK2 Receptor Activation in Stroke and PE Both disease processes improved through increased blood flow to ischemic tissue Mode of Action Receptor / Cell Type Stroke Increase Collateral Circulation in the Ischemic Penumbra Bradykinin2 Endothelial Receptor Cell Focal -
Slide 7: ReMEDy2 Phase 2/3 Trial Acute Ischemic Stroke
IQy z 4s ReMEDy2 Phase 2/3 Trial ai Acute Ischemic Stroke
Slide 8: High Unmet Need in Acute Ischemic Stroke
High Unmet Need in Acute Ischemic Stroke >7.5 million acute ischemic strokes globally® sa 80% of Patients with No Treatment Options Low Treatment Rates Us Annual Acute Ischemic Strokes}? 20% Active Treatment <140K Patients >500K Patients Limited Treatment Options 0 No New Pharmaceuticals Approved in
Slide 9: DM199 Initial Target in AIS - Significant Whitespace Opportunity
DM199 Initial Target in AIS - Significant Whitespace Opportunity >500k patients in the U.S. with no treatment option ) The 4.5-hour time window for tPA treatment significantly limits patient eligibility ) ~ 9096" of patients can reach the hospital emergency department within 24 hours 1 Hours 1 ‘Stro
Slide 10: Human Urinary KLK1 (HUK): Safe and Efficacious Treatment for AIS
Human Urinary KLK1 (HUK): Safe and Efficacious Treatment for AIS HUK guided DM199 development, informing optimal dosing, target patients, & treatment protocols Eros, Mea hs -/ MEDICAL RESEARCH, ) HUK for Als: — Marketed by Shanghai Pharmaceuticals under Kailikang®. Efficacy and safety of human — Ame
Slide 11: DM199 (rhKLK1 - Rinvecalinase Alfa) Novel Mechanism of Action
DM199 (rhKLK1 - Rinvecalinase Alfa) Novel Mechanism of Action Increased perfusion and other cardiovascular benefits BY > ininogen > KLK1 is made predominately in kidneys (present also in the vasculature and brain) and circulates in the blood. KLK1 acts on low molecular weight kininogen to produce br
Slide 12: Ischemia Naturally Induces Upregulation of Bradykinin (BK2) Receptors
Ischemia Naturally Induces Upregulation of Bradykinin 2 (BK2) Receptors DM199 enhances BK2 receptor activation to promote focal vasodilation in the penumbra Brain Artery Under Different Condition: Normal Conditions Conditic Conditions + DM199 aa ue ta rn ; ‘The BK2 receptor plays acrtical In respons
Slide 13: DM199 (rhKLK1): Collateral Circulation in Acute Ischemic Stroke
DM199 (rhKLK1): Collateral Cir in Acute Ischemic Stroke p Novel mechanism with potential to improve stroke outcomes & reduce risk of stroke recurrence DM199 does not need to pass. the blood-brain barrier to deliver therapeutic benefit. DM199 facilitates retease of endothelial nitric oxide and prosta
Slide 14: Human Urinary KLK1 (HUK) Improved Cerebral Blood Flow and Stroke Outcomes
Human Urinary KLK1 (HUK) Improved Cerebral Blood Flow and Stroke Outcomes MTT (Mean Transit Time) assesses blood flow velocity in the brain of AIS patients % Change in MTT Proportion of mRS <2 (Day 12vs. Baseline) (At 90 Days) 7 19.4% 72% 8 430.1% Poni é if 5 i z s & 2 GDiaMeaica
Slide 15: DM199 Phase 2 Results: Improved Excellent Outcomes in Non-MT Subgroup
DM199(rhKLK1) Phase 2 Results: Improved Excellent Outcomes in Non-MT Subgroup Patient population closely aligns with ReMEDy2 Phase 2/3 trial M199 (rhKLK1 ) Excellent Outcomes at 90 Days in Non-MT Pretreated Participants’ Ti Pracebo n=21) BB om29 (r=25) 36% 20% 80 Portcipants at Doy 9 5% a |_| | | mR
Slide 16: DM199 Phase 2 AIS Results Compared with Published tPA Data
DM199 (rhKLK1) Phase 2 AIS Results Compared with Published tPA Data Clinically relevant outcomes with DM199 extending treatment window 5X longer (NIHSS <1 and mRS <1) vs Placebo (0M199 and tPA analysis excludes MT treated participants) Trans seate(s3) ) tPA (Activase®) approved for AIS in 1996 a 2 M
Slide 17: DM199 Phase 2 AIS Results: Reduced Stroke Recurrence & Deaths
DM199 (rhKLK1) Phase 2 AIS Results: Reduced Stroke Recurrence & Deaths Supporting secondary endpoints in non-MT pretreated subgroup Stroke-in-Evolution / Recurrent Ischemic Events (Day 90) Deaths (Day 90) [BB Pcebo (n=23) BE vv199 0-25) 25% ‘hot Portcipents at Day 90 0.0% Absolute Decrease “19% 12%
Slide 18: DM199 (rhKLK1) Pivotal Phase 2/3 Trial
DM199 (rhKLK1) Pivotal Phase 2/3 Trial Key Eligibility Criteria ) Moderate AIS: NIHSS: 5-15, > N=~364 participants ~ Interim analysis @ 144 Screening Randomization = > 4:1 randomization ‘SweekTreatmentPeriod 90.0ayFolow-up Endpoints (Day 90) Primary: Modified Rankin Score (mRS) <1 ‘Secondary: mRS sh
Slide 19: Preeclampsia
2 n Q E 2 oO o o i a SY Zs
Slide 20: Preeclampsia: Significant Unmet Medical Need
Preeclampsia: Significant Unmet Medical Need No FDA approved therapies for preeclampsia Disease Overview Market Opportunity _— TT > ipsia is a life- > ypsia and related high blood pressure disorder that Iypertensive disorders of pregnancy occurs only during pregnancy and affect 5-886 of allbirths in
Slide 21: US Has Highest Maternal Death Rate Among High-Income Nations
US Has Highest Maternal Death Rate Among High-Income Nations US Black women disproportionately impacted - mortality rate >7x High-Income Nation average ‘Maternal deaths per 100,000 tive births 495 Mortality rates in the US are over three times higher than countries like the UK, France, and Germany 2
Slide 22: Strong Rationale for DM199 in Treating Pregnancy Complications
Strong Rationale for DM199 in Treating Pregnancy Complications Potential disease modifying therapy } ) DM199’s novel MOA addresses several pathophysiological mechanisms of preeclampsia and has the potential to be disease modifying © > omag9 has not been shown to cross placental barrier ) Completed f
Slide 23: DM199 Mode of Action in Preeclampsia
DM199 Mode of Action in Preeclampsia Targeting both upstream placental hypoxia & downstream endothelial dysfunction and blood pressure PLACENTAL DISEASE Pro-inflammatory DM199 Potential Mode of Action agian ines 7 totes ) Circutates in the maternal bloodstream without crossing the placental barrier
Slide 24: DM199 Shown to Reduce Blood Pressure and Not Cross Placental Barrier
DM199 Shown to Reduce Blood Pressure and Not Cross Placental Barrier M199 Phase 2 CKD Trial - Change in Blood Pressure 2&2, -esope190 “esepe140 ‘Baseline ram) Day 32 Day 64 Day 95 ‘Statistically significant reductions in systolic blood pressure (SBP) observed in participants with baseline levels 213
Slide 25: Planned DM199 Preeclampsia Phase 2 Trial (Tygerberg Hospital, Cape Town)
Planned DM199 Preeclampsia Phase 2 Trial (Tygerberg Hospital in Cape Town, South Africa)” Part 1: Women planned for delivery in 72 hours Part 1 Overview Study Groups 1A. up to 30 preeclampsia participants: Preeclampsiaparticipants: (MaPCHig Ascending dose study identifying the optimal = 27-42weeks g
Slide 26: Planned DM199 Preeclampsia Phase 2 Trial: Part 2
Planned DM199 Preeclampsia Phase 2 Trial” Part 2: Expectant management Part 2 Overview Study Group Preeclampsiaparticipants: (MUEaL 27-33 weeks gestation [ns Fe Ns be treated for ~ Followed by repeated) ————) 30 participants with preterm preeclampsia expectant management SC dose every 72 hours until
Slide 27: Corporate Summary
Corporate Summary "2 DiaMedica <- HERAPEUTICS
Slide 28: DM199 (Rinvecalinase Alfa) Multi-layered IP and Exclusivity Position
DM199 (Rinvecalinase Alfa) Multi-layered IP and Exclusivity Position Protein Development & Trade Secrets (M199 (rhKLK1): Excellent Enzymatic Activity & Highly Scalable ) Configuration of high & tow molecular ‘weight glcoforms critical for optimal activity ) Reproducible manufacturing process ) Modif
Slide 29: Leadership
Leadership CEO of DiaMedica since 2010. Former venture capitalist with two funds, including co-founder and managing director of Ufe sciences fund and eary investor in DMAC. Lorianne Masuioka, MD, Chief Medical Officer 25¢ years experience building and expanding high value pipelines in the biopharmac
Slide 30: Company Overview
Company Overview Cash: $46 million (as of March 31, 2024) Lead Program: DM199 - Novel, Late-Stage Biologic Therapy ). Recombinant KLK2 (rhKLK2) protein with FDA Fast-Track Designation > Acute Ischemic Stroke (AIS) ) >$10 billion US market opportunity 5 ) ~80% of patients have no treatment options to
Slide 31: Thank You!
Thank You! nasdaq: dmac www.diamedica.com
Slide 32: DM199 Phase 2/3 AIS Trial Adaptations Based on Phase 2 Results
g DM199 Phase 2/3 AIS Trial Adaptations Based on Phase 2 Results 2 ReMEDy2 Aligned Study Population to Target Patient Responders from Phase 2 and HUK-Treated Population ) Greater clinical benefit anticipated in patients who do not receive mechanical thrombectomy and/or tPA and moderate severity stro
DiaMedica Therapeutics — Investor Presentation (June 2024) on 6ix